

NDA 50-746/S-022

## SUPPLEMENT APPROVAL

SmithKline Beecham (Cork) Ltd, Ireland  
Attention: Dawn Adsit  
Regulatory Project Manager, Global Regulatory Affairs  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709

Dear Ms. Adsit:

Please refer to your supplemental new drug application (sNDA) dated June 7, 2019, received June 7, 2019, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for BACTROBAN (mupirocin) cream, 2%.

This Prior Approval supplemental new drug application provides for revisions to the established name(s) and equivalency statements in the prescribing information (PI) and carton and container labeling, to be in accordance with the USP salt policy. Specifically, the following sections of the PI have been revised: **DOSAGE FORMS AND STRENGTHS (3), DESCRIPTION (11), and HOW SUPPLIED/STORAGE AND HANDLING (16).**

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling, with minor editorial revisions.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>  
The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate the submissions “**Final Printed Carton and Container Labeling for approved NDA 50-746/S-022**”. Approval of this submission by FDA is not required before the labeling is used.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Maureen Dillon-Parker, MS, RAC, Chief, Regulatory Project Management Staff, at 301-796-0706.

Sincerely,

*{See appended electronic signature page}*

Dmitri Iarikov, MD, PhD  
Deputy Director  
Division of Anti-Infectives  
Office of Infectious Diseases  
Center for Drug Evaluation and Research

### **ENCLOSURE(S):**

- Content of Labeling/ Prescribing Information & Patient Package Insert
- Carton and Container Labeling

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

DMITRI IARIKOV  
02/19/2020 04:42:58 PM